儿童斑秃治疗的系统综述
该系统综述评估了儿童斑秃现有治疗方案的证据,共纳入122篇报告涉及1032例患者,其中仅2项随机对照试验。结论认为外用糖皮质激素是首选一线治疗,证据等级最高,其次是接触免疫疗法,需更多临床试验指导管理。
要点
- 外用糖皮质激素是儿童斑秃首选一线治疗,证据等级最高。
- 接触免疫疗法为次要推荐,其他疗法证据有限。
- 现有证据以病例系列和个案报道为主,急需高质量临床试验。
核心结论
- 外用糖皮质激素是儿童斑秃首选一线治疗,因其证据等级最高。
- 接触免疫疗法为第二推荐治疗。
- 需要更多临床试验和比较研究来指导儿童斑秃管理并促进现有低成本及新型疗法(包括JAK抑制剂)的潜在应用。
研究设计与样本
- 系统综述,检索PubMed数据库(2019年10月),纳入涉及18岁以下斑秃患者的已发表文章。
- 共纳入122篇报告,涉及1032例患者,包括2项随机对照试验、4项前瞻性比较队列、83项病例系列、2项病例对照研究和31项个案报道。
主要发现
- 纳入文章评估了芦荟、阿普斯特、蒽林、抗干扰素γ抗体、肉毒毒素、糖皮质激素、接触免疫疗法、冷冻疗法、羟氯喹、催眠疗法、咪喹莫特、Janus激酶抑制剂、激光和光疗、甲氨蝶呤、米诺地尔、光疗、心理治疗、前列腺素类似物、柳氮磺吡啶、外用钙调神经磷酸酶抑制剂、外用氮芥和乌司奴单抗等治疗。
关键数值与推荐
- 外用糖皮质激素为首选一线治疗,证据等级最高。
- 接触免疫疗法为第二推荐。
临床怎么用
- 临床可优先选用外用糖皮质激素治疗儿童斑秃。
- 接触免疫疗法可作为备选方案。
- 其他疗法证据有限,需结合个体情况谨慎选择。
局限性
- 仅纳入英文全文文章。
- 仅当提供儿童个体数据时才纳入成人和儿童混合数据的手稿。
- 未进行荟萃分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Alopecia areata (AA) is an autoimmune, nonscarring hair loss disorder with slightly greater prevalence in children than adults. Various treatment modalities exist; however, their evidence in pediatric AA patients is lacking. OBJECTIVE: To evaluate the evidence of current treatment modalities for pediatric AA. METHODS: We conducted a systematic review on the PubMed database in October 2019 for all published articles involving patients <18 years old. Articles discussing AA treatment in pediatric patients were included, as were articles discussing both pediatric and adult patients, if data on individual pediatric patients were available. RESULTS: Inclusion criteria were met by 122 total reports discussing 1032 patients. Reports consisted of 2 randomized controlled trials, 4 prospective comparative cohorts, 83 case series, 2 case-control studies, and 31 case reports. Included articles assessed the use of aloe, apremilast, anthralin, anti-interferon gamma antibodies, botulinum toxin, corticosteroids, contact immunotherapies, cryotherapy, hydroxychloroquine, hypnotherapy, imiquimod, Janus kinase inhibitors, laser and light therapy, methotrexate, minoxidil, phototherapy, psychotherapy, prostaglandin analogs, sulfasalazine, topical calcineurin inhibitors, topical nitrogen mustard, and ustekinumab. LIMITATIONS: English-only articles with full texts were used. Manuscripts with adult and pediatric data were only incorporated if individual-level data for pediatric patients were provided. No meta-analysis was performed. CONCLUSION: Topical corticosteroids are the preferred first-line treatment for pediatric AA, as they hold the highest level of evidence, followed by contact immunotherapy. More clinical trials and comparative studies are needed to further guide management of pediatric AA and to promote the potential use of pre-existing, low-cost, and novel therapies, including Janus kinase inhibitors.
引用
- Barton VR, Toussi A, Awasthi S, et al. Treatment of pediatric alopecia areata: A systematic review. J Am Acad Dermatol. 2021. PMID: 33940103. doi:10.1016/j.jaad.2021.04.077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。